With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street.However, the company ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. Two ...

A new investigational medication known as amycretin has shown significant potential in promoting weight loss, according to results from two early-stage clinical trials. By simultaneously activating ...

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, ...